Your search for ‘Sterne, Kessler, Goldstein & Fox P.L.L.C.’ returned 6 results

On November 2 and 3, 2010, the FDA held its first public hearing to obtain input on specific issues and challenges associated with the implementation of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which established an abbreviated approval pathway for generic versions of biological products.